@article{TonyBurmesterSchulzeKoopsetal.2011, author = {Tony, Hans-Peter and Burmester, Gerd and Schulze-Koops, Hendrik and Grunke, Mathias and Henes, Joerg and K{\"o}tter, Ina and Haas, Judith and Unger, Leonore and Lovric, Svjetlana and Haubitz, Marion and Fischer-Betz, Rebecca and Chehab, Gamal and Rubbert-Roth, Andrea and Specker, Christof and Weinerth, Jutta and Holle, Julia and M{\"u}ller-Ladner, Ulf and K{\"o}nig, Ramona and Fiehn, Christoph and Burgwinkel, Philip and Budde, Klemens and S{\"o}rensen, Helmut and Meurer, Michael and Aringer, Martin and Kieseier, Bernd and Erfurt-Berge, Cornelia and Sticherling, Michael and Veelken, Roland and Ziemann, Ulf and Strutz, Frank and von Wussow, Praxis and Meier, Florian MP and Hunzelmann, Nico and Schmidt, Enno and Bergner, Raoul and Schwarting, Andreas and Eming, R{\"u}diger and Schwarz-Eywill, Michael and Wassenberg, Siegfried and Fleck, Martin and Metzler, Claudia and Zettl, Uwe and Westphal, Jens and Heitmann, Stefan and Herzog, Anna L. and Wiendl, Heinz and Jakob, Waltraud and Schmidt, Elvira and Freivogel, Klaus and D{\"o}rner, Thomas and Hertl, Michael and Stadler, Rudolf}, title = {Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)}, series = {Arthritis Research \& Therapy}, volume = {13}, journal = {Arthritis Research \& Therapy}, number = {R75}, doi = {10.1186/ar3337}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-142856}, pages = {1-14}, year = {2011}, abstract = {Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0\% with systemic lupus erythematosus, 15.7\% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1\% multiple sclerosis and 10.0\% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0\% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3\% of patients showed no response, 45.1\% showed a partial response and 41.6\% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm)}, language = {en} } @phdthesis{Meier2020, author = {Meier, Michael}, title = {Synthese und Eigenschaften von funktionalisierten Borolen und 1,2-Azaborininen}, doi = {10.25972/OPUS-17840}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-178402}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2020}, abstract = {Im Rahmen dieser Arbeit konnte das Portfolio an literaturbekannten, freien Bisborolen betr{\"a}chtlich erweitert werden. Die Reihe der Oligothiophen-verbr{\"u}ckten Borole konnte um die Vertreter der Ter- bzw. Quaterthiophene erweitert werden. Weiterhin wurden Lewisbasenaddukte mit IMes, CAAC und DMAP dargestellt und zur r{\"o}ntgenspektrographischen Charakterisierung herangezogen. Durch den Vergleich der spektroskopischen Daten mit den bereits literaturbekannten Vertretern wurde eine schrittweise Entwicklung der Absorptionsmaxima in Abh{\"a}ngigkeit der Anzahl der Thienyleinheiten detektiert. Daraus konnte sowohl auf eine Verkleinerung der HOMO-LUMO-Abst{\"a}nde mit zunehmender Kettenl{\"a}nge, als auch die Entwicklung zu einem Grenzwert bei einer hypothetisch unendlichen Kettenl{\"a}nge geschlossen werden, welcher sich bei ca. ca. 2,40 eV befindet. Weiterhin wurden 9,9-Dimethylfluoren und Biphenyl erfolgreich zu Bisborolen umgesetzt. Beide Systeme sind aufgrund ihrer strukturellen Gemeinsamkeiten sowie ihrer Vergleichbarkeit mit literaturbekannten Bis(borolyl)benzol - Verbindungen von besonderem Interesse. Zudem konnte ein Vergleich der spektroskopischen Daten aller literaturbekannten und im Rahmen dieser Arbeit dargestellten Bisborole bewerkstelligt werden. Es wurde somit gezeigt, dass heteroaromatisch-verbr{\"u}ckte Bisborole eine gr{\"o}ßere energetische HOMO-LUMO-L{\"u}cke aufzeigen, als aromatisch-verbr{\"u}ckte Systeme. Zudem spielt die Position der Borolylgruppen und der damit verbundene Grad an pi-Interaktionen eine wichtige Rolle. Die beiden im Rahmen dieser Arbeit dargestellten Systeme 1,1'-(9,9-Dimethylfluoren-2,7-diyl)bis-(2,3,4,5-tetraphenylborol) und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl reihen sich energetisch zwischen dem 1,3- bzw. 1,4-Bis(2,3,4,5-tetraphenylborol-1-yl)benzol ein. Insbesondere der Vergleich zwischen 1,4-Bis(2,3,4,5-tetraphenylborol-1-yl)benzol und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl offenbart keine signifikante Energiedifferenz zwischen einer Phenyl- und einer Biphenylbr{\"u}cke, was ein Indiz daf{\"u}r darstellt, dass die Erweiterung des Spacers um eine zweite Phenyleinheit bei analoger 1,4-Verkn{\"u}pfung nahezu keinen Einfluss auf die elektronischen Eigenschaften des Systems hat. Auch die {\"U}berf{\"u}hrung von 1,1'-(9,9-Dimethylfluoren-2,7-diyl)bis-(2,3,4,5-tetraphenylborol) und 4,4'-Bis(2,3,4,5-tetraphenylborol-1-yl)-1,1'-biphenyl in die entsprechenden 1,2-Azaborinine wurde unter Verwendung von Trimethylsilylazid bewerkstelligt. Neben der Darstellung und Untersuchung neuer Bisborole wurde 9-(Thiophen-2-yl)carbazol erfolgreich f{\"u}r den Aufbau borhaltiger Donor-Akzeptor-Systeme eingesetzt. Es konnten im Zuge dessen ein Borol und dessen IMes-Addukt, ein 1,2-Azaborinin sowie ein Dimesitylboryl-substituiertes Derivat dargestellt und auf ihre optischen und elektronischen Eigenschaften hin untersucht werden. Dabei stand insbesondere die elektrochemische Quantifizierung der Elektronenakzeptorst{\"a}rke des Borols im Vergleich zum Dimesitylboran im Fokus. Es wurde ein signifikanter Unterschied des Borols (Epc = -1.60 V, CH2Cl2) im Vergleich zum Dimesitylboran (E1/2 = -2.39 V, THF) detektiert, woraus eine deutlich h{\"o}here Akzeptorst{\"a}rke des Borols abgeleitet werden kann. Zus{\"a}tzlich wurden spektroskopische und photophysikalische Untersuchungen in Abh{\"a}ngigkeit der jeweiligen Verbindung durchgef{\"u}hrt. Durch den Vergleich des energetisch niedrigsten Absorptionsmaximas des Borols mit bereits literaturbekannten, thienylsubstituierten Borolen konnte ein signifikanter Donoreinfluss der Carbazoleinheit best{\"a}tigt werden.}, subject = {Borheterocyclen}, language = {de} } @article{KochPetzoldWesselyetal.2021, author = {Koch, Elias A. T. and Petzold, Anne and Wessely, Anja and Dippel, Edgar and Gesierich, Anja and Gutzmer, Ralf and Hassel, Jessica C. and Haferkamp, Sebastian and Hohberger, Bettina and K{\"a}hler, Katharina C. and Knorr, Harald and Kreuzberg, Nicole and Leiter, Ulrike and Loquai, Carmen and Meier, Friedegund and Meissner, Markus and Mohr, Peter and Pf{\"o}hler, Claudia and Rahimi, Farnaz and Schadendorf, Dirk and Schell, Beatrice and Schlaak, Max and Terheyden, Patrick and Thoms, Kai-Martin and Schuler-Thurner, Beatrice and Ugurel, Selma and Ulrich, Jens and Utikal, Jochen and Weichenthal, Michael and Ziller, Fabian and Berking, Carola and Heppt, Markus}, title = {Immune checkpoint blockade for metastatic uveal melanoma: patterns of response and survival according to the presence of hepatic and extrahepatic metastasis}, series = {Cancers}, volume = {13}, journal = {Cancers}, number = {13}, issn = {2072-6694}, doi = {10.3390/cancers13133359}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-242603}, year = {2021}, abstract = {Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan-Meier method. Log-rank tests, χ\(^2\) tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95\% CI 13.4-23.7) and the median PFS, 2.8 months (95\% CI 2.5-3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8\% and to anti-PD-1 monotherapy 8.9\% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7\% vs. cohort B 16.7\%; p = 0.45). Adverse events (AE) occurred in 41.6\%. Severe AE were observed in 26.3\% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.}, language = {en} } @article{LoddeForschnerHasseletal.2021, author = {Lodde, Georg and Forschner, Andrea and Hassel, Jessica and Wulfken, Lena M. and Meier, Friedegund and Mohr, Peter and K{\"a}hler, Katharina and Schilling, Bastian and Loquai, Carmen and Berking, Carola and H{\"u}ning, Svea and Schatton, Kerstin and Gebhardt, Christoffer and Eckardt, Julia and Gutzmer, Ralf and Reinhardt, Lydia and Glutsch, Valerie and Nikfarjam, Ulrike and Erdmann, Michael and Stang, Andreas and Kowall, Bernd and Roesch, Alexander and Ugurel, Selma and Zimmer, Lisa and Schadendorf, Dirk and Livingstone, Elisabeth}, title = {Factors influencing the adjuvant therapy decision: results of a real-world multicenter data analysis of 904 melanoma patients}, series = {Cancers}, volume = {13}, journal = {Cancers}, number = {10}, issn = {2072-6694}, doi = {10.3390/cancers13102319}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239583}, year = {2021}, abstract = {Adjuvant treatment of melanoma patients with immune-checkpoint inhibition (ICI) and targeted therapy (TT) significantly improved recurrence-free survival. This study investigates the real-world situation of 904 patients from 13 German skin cancer centers with an indication for adjuvant treatment since the approval of adjuvant ICI and TT. From adjusted log-binomial regression models, we estimated relative risks for associations between various influence factors and treatment decisions (adjuvant therapy yes/no, TT vs. ICI in BRAF mutant patients). Of these patients, 76.9\% (95\% CI 74-80) opted for a systemic adjuvant treatment. The probability of starting an adjuvant treatment was 26\% lower in patients >65 years (RR 0.74, 95\% CI 68-80). The most common reasons against adjuvant treatment given by patients were age (29.4\%, 95\% CI 24-38), and fear of adverse events (21.1\%, 95\% CI 16-28) and impaired quality of life (11.9\%, 95\% CI 7-16). Of all BRAF-mutated patients who opted for adjuvant treatment, 52.9\% (95\% CI 47-59) decided for ICI. Treatment decision for TT or ICI was barely associated with age, gender and tumor stage, but with comorbidities and affiliated center. Shortly after their approval, adjuvant treatments have been well accepted by physicians and patients. Age plays a decisive role in the decision for adjuvant treatment, while pre-existing autoimmune disease and regional differences influence the choice between TT or ICI.}, language = {en} } @article{KochPetzoldWesselyetal.2022, author = {Koch, Elias A. T. and Petzold, Anne and Wessely, Anja and Dippel, Edgar and Gesierich, Anja and Gutzmer, Ralf and Hassel, Jessica C. and Haferkamp, Sebastian and K{\"a}hler, Katharina C. and Knorr, Harald and Kreuzberg, Nicole and Leiter, Ulrike and Loquai, Carmen and Meier, Friedegund and Meissner, Markus and Mohr, Peter and Pf{\"o}hler, Claudia and Rahimi, Farnaz and Schadendorf, Dirk and Schell, Beatrice and Schlaak, Max and Terheyden, Patrick and Thoms, Kai-Martin and Schuler-Thurner, Beatrice and Ugurel, Selma and Ulrich, Jens and Utikal, Jochen and Weichenthal, Michael and Ziller, Fabian and Berking, Carola and Heppt, Markus V.}, title = {Immune checkpoint blockade for metastatic uveal melanoma: re-induction following resistance or toxicity}, series = {Cancers}, volume = {14}, journal = {Cancers}, number = {3}, issn = {2072-6694}, doi = {10.3390/cancers14030518}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-254814}, year = {2022}, abstract = {Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95\% CI: 11.1-23.8) versus 9.4 months (cohort B, 95\% CI: 6.1-14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.}, language = {en} } @article{MeierKruseButtlaretal.2016, author = {Meier, Doreen and Kruse, Janis and Buttlar, Jann and Friedrich, Michael and Zenk, Fides and Boesler, Benjamin and Forstner, Konrad U. and Hammann, Christian and Nellen, Wolfgang}, title = {Analysis of the Microprocessor in Dictyostelium: The Role of RbdB, a dsRNA Binding Protein}, series = {PLoS Genetics}, volume = {12}, journal = {PLoS Genetics}, number = {6}, doi = {10.1371/journal.pgen.1006057}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166687}, pages = {e1006057}, year = {2016}, abstract = {We identified the dsRNA binding protein RbdB as an essential component in miRNA processing in Dictyostelium discoideum. RbdB is a nuclear protein that accumulates, together with Dicer B, in nucleolar foci reminiscent of plant dicing bodies. Disruption of rbdB results in loss of miRNAs and accumulation of primary miRNAs. The phenotype can be rescued by ectopic expression of RbdB thus allowing for a detailed analysis of domain function. The lack of cytoplasmic dsRBD proteins involved in miRNA processing, suggests that both processing steps take place in the nucleus thus resembling the plant pathway. However, we also find features e.g. in the domain structure of Dicer which suggest similarities to animals. Reduction of miRNAs in the rbdB- strain and their increase in the Argonaute A knock out allowed the definition of new miRNAs one of which appears to belong to a new non-canonical class.}, language = {en} }